All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @heal_withb on TikTok · 366s|Watch on TikTok

@heal_withb's Ozempic experience raises real concerns

Heal with B

TikTok creator

97.8K viewsWatch on TikTok

Quick answer

Semaglutide (Ozempic) is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite, leading to average weight loss of 14.9% in clinical trials. However, 74% of participants in the STEP 1 trial experienced gastrointestinal side effects, with some developing persistent complications like gastroparesis even after discontinuation.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @heal_withb's Ozempic experience raises real concerns, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@heal_withb's Ozempic experience raises real concerns" from Heal with B. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide (Ozempic) is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite, leading to average weight loss of 14.

The reason this review is not generic is the source wording and the canonical claim label "glp1 going on ozempic was one of the worst decisions i ve ever ma." In this clip, the useful excerpt is: "Going on Ozempic was one of the WORST decisions I've ever made." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Gastroparesis (stomach paralysis) can persist for months after stopping semaglutide, with limited treatment options available
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide (Ozempic) is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite, leading to average weight loss of 14.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide (Ozempic) is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite, leading to average weight loss of 14.9% in clinical trials. However, 74% of participants in the STEP 1 trial experienced gastrointestinal side effects, with some developing persistent complications like gastroparesis even after discontinuation.
  • 74% of STEP 1 trial participants experienced gastrointestinal side effects from semaglutide, with 7% discontinuing due to adverse events
  • Gastroparesis (stomach paralysis) can persist for months after stopping semaglutide, with limited treatment options available

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • 74% of STEP 1 trial participants experienced gastrointestinal side effects from semaglutide, with 7% discontinuing due to adverse events
  • Gastroparesis (stomach paralysis) can persist for months after stopping semaglutide, with limited treatment options available
  • The SUSTAIN trials documented increased risks of pancreatitis, gallbladder problems, and kidney complications compared to placebo
  • Many patients report inadequate counseling about serious long-term side effects before starting treatment
  • Real-world prescribing often lacks the extensive monitoring protocols used in clinical trials
  • Ask specifically about gastroparesis risk and post-discontinuation complications before starting semaglutide
  • Ensure your prescribing doctor has experience managing semaglutide complications, not just prescribing the medication

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this TikTok creator claim about Ozempic?

@heal_withb says taking Ozempic was "one of the WORST decisions" she's ever made and that she didn't do proper research beforehand. She also claims doctors haven't been able to help her with side effects or her underlying endometriosis.

The video doesn't specify what negative effects she experienced from semaglutide. She connects her bad experience to broader frustrations with healthcare for chronic conditions like endometriosis and PCOS.

Are serious Ozempic side effects actually documented?

Yes, clinical trials show semaglutide can cause significant side effects that persist even after stopping the medication. The STEP 1 trial (Wilding et al., NEJM, 2021) found 74% of participants experienced gastrointestinal side effects including nausea, diarrhea, and vomiting.

More concerning are emerging reports of gastroparesis (stomach paralysis) that can last months after discontinuation. A 2023 study in JAMA found increased risk of gastrointestinal complications compared to other weight loss medications.

The SUSTAIN trials also documented cases of pancreatitis, gallbladder problems, and kidney issues. These aren't rare outliers but documented risks that some patients experience severely.

Does the healthcare system adequately prepare patients?

This is where the creator makes her strongest point. Many patients report being inadequately counseled about potential long-term effects before starting semaglutide.

The prescribing information lists gastroparesis and other serious side effects, but anecdotal reports suggest rushed consultations don't always cover these thoroughly. The STEP trials required extensive monitoring that often doesn't happen in real-world prescribing.

Her frustration about doctors being unable to help with persistent side effects also rings true. There's limited research on treating post-semaglutide gastroparesis or other lasting complications.

What's missing from her account?

The creator doesn't specify her indication for taking Ozempic or whether she was using it off-label for weight loss versus diabetes management. This context matters for risk-benefit analysis.

She also doesn't detail which specific side effects she experienced or their timeline. Without knowing whether she had gastroparesis, severe nausea, or other documented complications, it's hard to evaluate her experience against known data.

Her comment about not doing research beforehand suggests some personal responsibility, though this doesn't excuse inadequate medical counseling if that occurred.

What should potential users actually know?

The STEP and SUSTAIN trials show semaglutide works for weight loss and diabetes management, but side effects are common and can be severe. About 7% of STEP 1 participants discontinued due to adverse events.

If you're considering semaglutide, ask specifically about gastroparesis risk, gallbladder complications, and what happens if you need to stop suddenly. Get clear protocols for managing side effects before they occur.

The creator's experience with unhelpful follow-up care is unfortunately common. Make sure your prescribing doctor has experience managing semaglutide complications, not just prescribing it.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Heal with B · TikTok creator

97.8K views on this video

Going on Ozempic was one of the WORST decisions I’ve ever made. I didn’t do my research. No doctors been able to help me before or since with this or my endo. Americas health care system has failed us

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about 74% of step 1 trial participants experienced gastrointestinal side effects?

74% of STEP 1 trial participants experienced gastrointestinal side effects from semaglutide, with 7% discontinuing due to adverse events

What does the video say about gastroparesis (stomach paralysis) can persist for months after stopping semaglutide,?

Gastroparesis (stomach paralysis) can persist for months after stopping semaglutide, with limited treatment options available

What does the video say about the sustain trials documented increased risks of pancreatitis, gallbladder problems,?

The SUSTAIN trials documented increased risks of pancreatitis, gallbladder problems, and kidney complications compared to placebo

What does the video say about many patients report inadequate counseling about serious long-term side effects?

Many patients report inadequate counseling about serious long-term side effects before starting treatment

What does the video say about real-world prescribing often lacks the extensive monitoring protocols used in?

Real-world prescribing often lacks the extensive monitoring protocols used in clinical trials

What does the video say about ask specifically about gastroparesis risk?

Ask specifically about gastroparesis risk and post-discontinuation complications before starting semaglutide

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Heal with B, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.